Annual Review Course Live Course Only (2023)
Availability
No future session
Expires on Jun 04, 2026
Cost
$0.00
Credit Offered
24.25 AMA PRA Category 1 Credit Credits
24.25 Participation Credits

For the ABU Qualifying (Part 1) Examination, residents need to possess basic urologic knowledge and an understanding of current American Urological Association practice guidelines. To fulfill this need, the AUA developed this course to disseminate current urologic knowledge and successfully prepare residents for the ABU examination. This course is also of interest to practicing urologists preparing as well as others, including allied health professionals, looking for a thorough review of basic urologic topics.

Get the most out of your study time and preparation by marking off your calendar and registering for the Live Course!

The 2023 Live Program Includes:

  • Live Presentations
  • Audience Interaction
  • Q&A
  • Polling/ Practice Questions

AUA Guarantee: This course is backed by the AUA Guarantee: If you fail the boards, then we will pay for you to retake our in person course. (Applicable 2022 registrants please call 1-800-908-9414)


Registration Fees

Membership Category

Early Bird Registration-Extended!

On or Before April 21, 2023

Standard Registration

On or After April 22, 2023

Member$945$1180
Non-Member$1180$1475
Member Resident/Allied$525$655
Non-Member Resident/Allied$655$820
  • Residents
  • Urologists

At the conclusion of this course, participants will be able to:

  1. Apply basic, generally accepted urological practices for effective, high-quality patient care.
  2. Demonstrate core knowledge of urology necessary for American Board of Urology (ABU) Qualifying (Part 1) Examination.
  3. Utilize AUA Guidelines for appropriate patient evaluation and management.

Education Council Disclosures

Education Council Disclosures_2022.pdf

COI Review Work Group Disclosures

COI Review Work Group Disclosures_2022.pdf

 
 
Course Co-director(s)

Howard Goldman, MD  

financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with allergan;
 
financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Medtronic;
 
financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with NewUro;
 
financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Bluewind;
 
financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Boston Scientific;
 
financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Laborie;
 
financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with urovant;
 
financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with sacramed;
 
financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with vensica;
 
financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Direx.

Kristen Scarpato, MD

has a financial relationship (Consultant or Advisor (Oncology)) with Optum;
 
financial relationship (Consultant or Advisor (Oncology)) with CxBladder;
 
financial relationship (Meeting Participant or Lecturer (Oncology)) with Photocure.

Faculty(s)

Nicholas Cowan, MD

has no relevant financial relationships to disclose at this time.

Mantu Gupta, MD

has a financial relationship (Meeting Participant or Lecturer (Specialty Not Specified)) with Cook Urological;
 
financial relationship (Consultant or Advisor (Specialty Not Specified)) with Olympus;
 
financial relationship (Meeting Participant or Lecturer (Specialty Not Specified)) with Boston Scientific Inc;
 
financial relationship (Meeting Participant or Lecturer (Specialty Not Specified)) with Retrophin Inc.

Alexander Kutikov, MD

 has no relevant financial relationships to disclose at this time.

Armando Lorenzo, MD, FAAP, FACS, FRCSC, MSC

has no relevant financial relationships to disclose at this time.

Timothy Masterson, MD

 
has no relevant financial relationships to disclose at this time.

Akanksha Mehta, MD

 
has a financial relationship (Other (Male Infertility)) with Posterity Health.

Anne Pelletier Cameron, MD

 
has a financial relationship (Health Publishing (Female Pelvic Medicine & Reconstructive Surgery)) with Springer;
 
financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Axonics;
 
financial relationship (Other (Female Pelvic Medicine & Reconstructive Surgery)) with Wellspect;
 
financial relationship (Health Publishing (Female Pelvic Medicine & Reconstructive Surgery)) with Wiley.

Michel Pontari, MD

 
has no relevant financial relationships to disclose at this time.

Vinay Prabhu, MD

 
has a financial relationship (Investment Interest (Oncology)) with Gilead;
 
financial relationship (Investment Interest (General Urology)) with Abbvie;
 
financial relationship (Investment Interest (Non-urology Healthcare Related)) with QIAGEN;
 
financial relationship (Investment Interest (Non-urology Healthcare Related)) with Moderna;
 
financial relationship (Investment Interest (Non-urology Healthcare Related)) with Sanofi.

Bruce Schlomer, MD

 
has no relevant financial relationships to disclose at this time.

Jay Simhan, MD

 
has a financial relationship (Meeting Participant or Lecturer (Erectile Dysfunction)) with Boston Scientific ;
 
financial relationship (Meeting Participant or Lecturer (Erectile Dysfunction)) with Coloplast.

Jennifer Taylor, MD

 
has a financial relationship (Scientific Study or Trial (Oncology)) with Photocure Inc;
 
financial relationship (Health Publishing (Oncology)) with Demos Medical Publishing.

Robert Uzzo, MD

 
has a financial relationship (Other (Oncology)) with Pfizer;
 
financial relationship (Consultant or Advisor (Oncology)) with UroGen Pharma;
 
financial relationship (Scientific Study or Trial (Oncology)) with Merck.

Sarah Vij, MD

 
has no relevant financial relationships to disclose at this time.

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

AUA ACCREDITATION INFORMATION

ACCREDITATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this live activity for a maximum of 24.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditsTM.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY:

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.